Investment Company Report

Meeting Date Range: 01-Jul-2025 - 30-Jun-2026 **Report Date:** 27-Aug-2026

Portland Life Sciences Alternative Fund

AMGEN INC.

Security:	031162100	**Agenda Number:**	936431953
Ticker:	AMGN	**Meeting Type:**	Annual
ISIN:	US0311621009	**Meeting Date:**	19-May-26

Prop. #	Proposal	Proposed by	Proposal Vote	For/Against Management's Recommendation
1a.	To elect twelve directors to the Board of Directors of Amgen Inc. for a term of office expiring at the 2027 annual meeting of stockholders. The nominees for election to the Board of Directors are: Dr. Wanda M. Austin Enhanced Proposal Category: Elect Director	Mgmt	For	For
1b.	To elect twelve directors to the Board of Directors of Amgen Inc. for a term of office expiring at the 2027 annual meeting of stockholders. The nominees for election to the Board of Directors are: Mr. Robert A. Bradway Enhanced Proposal Category: Elect Director	Mgmt	For	For
1c.	To elect twelve directors to the Board of Directors of Amgen Inc. for a term of office expiring at the 2027 annual meeting of stockholders. The nominees for election to the Board of Directors are: Dr. Michael V. Drake Enhanced Proposal Category: Elect Director	Mgmt	For	For
1d.	To elect twelve directors to the Board of Directors of Amgen Inc. for a term of office expiring at the 2027 annual meeting of stockholders. The nominees for election to the Board of Directors are: Dr. Brian J. Druker Enhanced Proposal Category: Elect Director	Mgmt	For	For
1e.	To elect twelve directors to the Board of Directors of Amgen Inc. for a term of office expiring at the 2027 annual meeting of stockholders. The nominees for election to the Board of Directors are: Mr. Robert A. Eckert Enhanced Proposal Category: Elect Director	Mgmt	For	For
1f.	To elect twelve directors to the Board of Directors of Amgen Inc. for a term of office expiring at the 2027 annual meeting of stockholders. The nominees for election to the Board of Directors are: Mr. Greg C. Garland Enhanced Proposal Category: Elect Director	Mgmt	For	For

Investment Company Report

Prop. #	Proposal	Proposed by	Proposal Vote	For/Against Management's Recommendation
1g.	To elect twelve directors to the Board of Directors of Amgen Inc. for a term of office expiring at the 2027 annual meeting of stockholders. The nominees for election to the Board of Directors are: Mr. Charles M. Holley, Jr.	Mgmt	For	For
	Enhanced Proposal Category: Elect Director			
1h.	To elect twelve directors to the Board of Directors of Amgen Inc. for a term of office expiring at the 2027 annual meeting of stockholders. The nominees for election to the Board of Directors are: Dr. S. Omar Ishrak	Mgmt	For	For
	Enhanced Proposal Category: Elect Director			
1i.	To elect twelve directors to the Board of Directors of Amgen Inc. for a term of office expiring at the 2027 annual meeting of stockholders. The nominees for election to the Board of Directors are: Dr. Tyler Jacks	Mgmt	For	For
	Enhanced Proposal Category: Elect Director			
1j.	To elect twelve directors to the Board of Directors of Amgen Inc. for a term of office expiring at the 2027 annual meeting of stockholders. The nominees for election to the Board of Directors are: Dr. Mary E. Klotman	Mgmt	For	For
	Enhanced Proposal Category: Elect Director			
1k.	To elect twelve directors to the Board of Directors of Amgen Inc. for a term of office expiring at the 2027 annual meeting of stockholders. The nominees for election to the Board of Directors are: Ms. Ellen J. Kullman	Mgmt	For	For
	Enhanced Proposal Category: Elect Director			
1l.	To elect twelve directors to the Board of Directors of Amgen Inc. for a term of office expiring at the 2027 annual meeting of stockholders. The nominees for election to the Board of Directors are: Ms. Amy E. Miles	Mgmt	For	For
	Enhanced Proposal Category: Elect Director			
2.	Advisory vote to approve our executive compensation.	Mgmt	For	For
	Enhanced Proposal Category: Advisory Vote to Ratify Named Executive Officers' Compensation			

Investment Company Report

Meeting Date Range: 01-Jul-2025 - 30-Jun-2026 **Report Date:** 27-Aug-2026

Prop. #	Proposal	Proposed by	Proposal Vote	For/Against Management's Recommendation
3.	To ratify the selection of Ernst & Young LLP as our independent registered public accountants for the fiscal year ending December 31, 2026. Enhanced Proposal Category: Ratify Auditors	Mgmt	For	For
4.	Stockholder proposal to require an independent board chairman. Enhanced Proposal Category: Require Independent Board Chair	Shr	Against	For

Account Number	Custodian	Ballot Shares	Voted Shares	Shares on Loan	Vote Date
000131268	BNY	250	250	0	15-May-26
00047580695 ! 5RY0	RBCC	1250	1250	0	15-May-26

Investment Company Report

Meeting Date Range: 01-Jul-2025 - 30-Jun-2026 **Report Date:** 27-Aug-2026

Portland Life Sciences Alternative Fund

ARVINAS, INC.

Security:	04335A105	**Agenda Number:**	936480235
Ticker:	ARVN	**Meeting Type:**	Annual
ISIN:	US04335A1051	**Meeting Date:**	24-Jun-26

Prop. #	Proposal	Proposed by	Proposal Vote	For/Against Management's Recommendation
1.	DIRECTOR			
	Enhanced Proposal Category: Elect Director			
	1 Leslie V. Norwalk, Esq.	Mgmt	For	For
	2 Randy Teel, Ph.D.	Mgmt	For	For
2.	To approve, on an advisory basis, the compensation of the Company's named executive officers.	Mgmt	For	For
	Enhanced Proposal Category: Advisory Vote to Ratify Named Executive Officers' Compensation			
3.	Ratification of the appointment of Deloitte & Touche LLP as the Company's Independent registered public accounting firm for the fiscal year ending December 31, 2026.	Mgmt	For	For
	Enhanced Proposal Category: Ratify Auditors			

Account Number	Custodian	Ballot Shares	Voted Shares	Shares on Loan	Vote Date
000131268	BNY	14000	14000	0	23-Jun-26

Investment Company Report

Portland Life Sciences Alternative Fund

BEONE MEDICINES, LTD. (FKA BEIGENE)

Security:	07725L102	**Agenda Number:**	936500900
Ticker:	ONC	**Meeting Type:**	Annual
ISIN:	US07725L1026	**Meeting Date:**	11-Jun-26

Prop. #	Proposal	Proposed by	Proposal Vote	For/Against Management's Recommendation
1.	THAT - the audited Swiss statutory standalone financial statements and the audited Swiss statutory consolidated financial statements of the Company for fiscal year 2025 be and are hereby approved.	Mgmt	For	For
	Enhanced Proposal Category: Accept Financial Statements and Statutory Reports			
2.	THAT - the appropriation of the accumulated loss for fiscal year 2025 be and is hereby approved.	Mgmt	For	For
	Enhanced Proposal Category: Approve Treatment of Net Loss			
3.	THAT - the members of the Board of Directors and the Executive Management Team be and are hereby discharged from liability for activities during the applicable period under Swiss law.	Mgmt	For	For
	Enhanced Proposal Category: Approve Discharge of Board and President (Bundled)			
4a.	THAT - Dr. Olivier Brandicourt be and is hereby re-elected to serve as a director of the Company for a term extending until completion of the 2027 annual general meeting. Dr. Olivier Brandicourt	Mgmt	For	For
	Enhanced Proposal Category: Elect Director			
4b.	THAT - Dr. Margaret Dugan be and is hereby re-elected to serve as a director of the Company for a term extending until completion of the 2027 annual general meeting. Dr. Margaret Dugan	Mgmt	For	For
	Enhanced Proposal Category: Elect Director			
4c.	THAT - Mr. Anthony C. Hooper be and is hereby re-elected to serve as a director of the Company for a term extending until completion of the 2027 annual general meeting. Mr. Anthony C. Hooper	Mgmt	For	For
	Enhanced Proposal Category: Elect Director			

Investment Company Report

Meeting Date Range: 01-Jul-2025 - 30-Jun-2026 **Report Date:** 27-Aug-2026

Prop. #	Proposal	Proposed by	Proposal Vote	For/Against Management's Recommendation
4d.	THAT - Mr. John V. Oyler be and is hereby re-elected to serve as a director of the Company for a term extending until completion of the 2027 annual general meeting. Mr. John V. Oyler Enhanced Proposal Category: Elect Director	Mgmt	For	For
4e.	THAT - Dr. Alessandro Riva be and is hereby re-elected to serve as a director of the Company for a term extending until completion of the 2027 annual general meeting. Dr. Alessandro Riva Enhanced Proposal Category: Elect Director	Mgmt	For	For
4f.	THAT - Ms. Shalini Sharp be and is hereby re-elected to serve as a director of the Company for a term extending until completion of the 2027 annual general meeting. Ms. Shalini Sharp Enhanced Proposal Category: Elect Director	Mgmt	For	For
4g.	THAT - Dr. Xiaodong Wang be and is hereby re-elected to serve as a director of the Company for a term extending until completion of the 2027 annual general meeting. Dr. Xiaodong Wang Enhanced Proposal Category: Elect Director	Mgmt	For	For
4h.	THAT - Dr. Felix J. Baker be and is hereby elected to serve as a director of the Company for a term extending until completion of the 2027 annual general meeting. Dr. Felix J. Baker Enhanced Proposal Category: Elect Director	Mgmt	For	For
4i.	THAT - Ms. Elizabeth F. Mooney be and is hereby elected to serve as a director of the Company for a term extending until completion of the 2027 annual general meeting. Ms. Elizabeth F. Mooney Enhanced Proposal Category: Elect Director	Mgmt	For	For
4j.	THAT - Dr. Charles L. Sawyers be and is hereby elected to serve as a director of the Company for a term extending until completion of the 2027 annual general meeting. Dr. Charles L. Sawyers Enhanced Proposal Category: Elect Director	Mgmt	For	For

Prop. #	Proposal	Proposed by	Proposal Vote	For/Against Management's Recommendation
5.	THAT - Mr. John V. Oyler be and is hereby re-elected to serve as Chairman of the Board of Directors of the Company for a term extending until completion of the 2027 annual general meeting.	Mgmt	For	For
	Enhanced Proposal Category: Elect Board Chair or Vice-Chair			
6a.	THAT - Dr. Margaret Dugan be and is hereby re-elected to serve as a member of the Compensation Committee of the Company for a term extending until completion of the 2027 annual general meeting.	Mgmt	For	For
	Enhanced Proposal Category: Elect Member of Remuneration Committee			
6b.	THAT - Ms. Elizabeth F. Mooney be and is hereby elected to serve as a member of the Compensation Committee of the Company for a term extending until completion of the 2027 annual general meeting.	Mgmt	For	For
	Enhanced Proposal Category: Elect Member of Remuneration Committee			
7.	THAT - Schweiger Advokatur/Notariat be and is hereby elected to serve as the Independent Voting Representative for a one-year term ending at the closing of the 2027 annual general meeting of shareholders, including any extraordinary general meeting of shareholders prior to the 2027 annual general meeting of shareholders.	Mgmt	For	For
	Enhanced Proposal Category: Designate X as Independent Proxy			
8.	THAT- the appointment of Ernst & Young LLP, Ernst & Young and Ernst & Young Hua Ming LLP as the Company's independent auditors for the fiscal year ending December 31, 2026 be and is hereby ratified, and Ernst & Young AG be and is hereby re-elected as the Company's statutory auditor for the fiscal year ending December 31, 2026.	Mgmt	For	For
	Enhanced Proposal Category: Ratify Auditors			
9.	THAT - the Board of Directors is hereby authorized to fix the auditors' compensation for the fiscal year ending December 31, 2026.	Mgmt	For	For
	Enhanced Proposal Category: Authorize Board to Fix Remuneration of External Auditor(s)			

Prop. #	Proposal	Proposed by	Proposal Vote	For/Against Management's Recommendation
10.	THAT, - on a non-binding, advisory basis, the compensation of the Company's named executive officers, as disclosed in the Proxy Statement, for the fiscal year ended December 31, 2025 be and is hereby approved.	Mgmt	For	For
	Enhanced Proposal Category: Advisory Vote to Ratify Named Executive Officers' Compensation			
11.	THAT, - the maximum aggregate compensation for the Board of Directors for the period between the 2026 annual general meeting and the 2027 annual general meeting, be and is hereby approved.	Mgmt	For	For
	Enhanced Proposal Category: Approve Remuneration of Directors and/or Committee Members			
12.	THAT, - the maximum aggregate compensation for the Executive Management Team for fiscal year 2027 be and is hereby approved.	Mgmt	For	For
	Enhanced Proposal Category: Approve Remuneration of Executive Directors and/or Non-Executive Directors			
13.	THAT, - on an advisory basis, the Swiss Statutory Compensation Report for the fiscal year ended December 31, 2025 be and is hereby approved.	Mgmt	For	For
	Enhanced Proposal Category: Advisory Vote to Ratify Named Executive Officers' Compensation			
14.	THAT, - on an advisory basis, the Swiss Statutory Non-Financial Matters Report for the fiscal year ended December 31, 2025 be and is hereby approved.	Mgmt	For	For
	Enhanced Proposal Category: Accept/Approve Corporate Social Responsibility Report			
15a	THAT - the Fifth Amended and Restated 2016 Share Option and Incentive Plan be and is hereby approved.	Mgmt	For	For
	Enhanced Proposal Category: Amend Omnibus Stock Plan			
15b	THAT - the consultant sublimit in the Fifth Amended and Restated 2016 Share Option and Incentive Plan be and is hereby approved.	Mgmt	For	For
	Enhanced Proposal Category: Amend Omnibus Stock Plan			
16.	THAT - the Sixth Amended and Restated 2018 Employee Share Purchase Plan be and is hereby approved.	Mgmt	For	For
	Enhanced Proposal Category: Amend Qualified Employee Stock Purchase Plan			

Prop. #	Proposal	Proposed by	Proposal Vote	For/Against Management's Recommendation
17.	THAT - the granting of a share issue mandate to the Board of Directors to issue, allot or deal with unissued ordinary shares and/or American Depositary Shares ("ADSs") (including any sale or transfer of treasury shares out of treasury) not exceeding 20% of the total number of issued shares of the Company (excluding treasury shares) as of the date of passing of this resolution up to the next annual general meeting of shareholders of the Company be and is hereby approved.	Mgmt	For	For
	Enhanced Proposal Category: Approve Issuance of Equity or Equity-Linked Securities without Preemptive Rights			
18.	THAT - the granting of a share repurchase mandate to the Board of Directors to repurchase an amount of ordinary shares (excluding the Company's ordinary shares listed on the Science and Technology Innovation Board of Shanghai Stock Exchange and traded in RMB ("RMB shares")) and/or ADSs, not exceeding 10% of the total number of issued ordinary shares (excluding RMB shares and treasury shares) of the Company as of the date of passing of this resolution up to the next annual general meeting of shareholders of the Company be and is hereby approved.	Mgmt	For	For
	Enhanced Proposal Category: Authorize Share Repurchase Program			
19.	THAT - the Company and its underwriters be and are hereby authorized, in their sole discretion, to allocate to Amgen Inc. ("Amgen"), up to a maximum amount of shares in order to maintain the same shareholding percentage of Amgen (based on the then-outstanding share capital of the Company) before and after the allocation of the corresponding securities issued pursuant to an offering conducted pursuant to the general mandate set forth in Resolution 17 for a period of five years, which period will be subject to an extension on a rolling basis each year.	Mgmt	For	For
	Enhanced Proposal Category: Company Specific - Equity Related			

Investment Company Report

Prop. #	Proposal	Proposed by	Proposal Vote	For/Against Management's Recommendation
20.	THAT - the adjournment of the Annual Meeting by the chairman, if necessary, to solicit additional proxies if there are insufficient votes at the time of the Annual Meeting to approve any of the proposals described above, be and is hereby approved. Enhanced Proposal Category: Adjourn Meeting	Mgmt	For	For

Account Number	Custodian	Ballot Shares	Voted Shares	Shares on Loan	Vote Date
000131268	BNY	3000	3000	0	01-Jun-26

Investment Company Report

Meeting Date Range: 01-Jul-2025 - 30-Jun-2026 **Report Date:** 27-Aug-2026

Portland Life Sciences Alternative Fund

BICYCLE THERAPEUTICS PLC

Security:	088786108	**Agenda Number:**	936473571
Ticker:	BCYC	**Meeting Type:**	Annual
ISIN:	US0887861088	**Meeting Date:**	17-Jun-26

Prop. #	Proposal	Proposed by	Proposal Vote	For/Against Management's Recommendation
1.	To re-elect as a director Felix Baker, who retires in accordance with the Articles of Association. Felix Baker	Mgmt	For	For
	Enhanced Proposal Category: Elect Director			
2.	To re-elect as a director Hervé Hoppenot, who retires in accordance with the Articles of Association. Hervé Hoppenot	Mgmt	For	For
	Enhanced Proposal Category: Elect Director			
3.	To approve, on advisory basis, the compensation of our named executive officers, as disclosed in the proxy statement.	Mgmt	For	For
	Enhanced Proposal Category: Advisory Vote to Ratify Named Executive Officers' Compensation			
4.	To ratify the appointment of PricewaterhouseCoopers LLP, a limited liability partnership organized under the laws of England, as our independent registered public accounting firm for the year ending December 31, 2026.	Mgmt	For	For
	Enhanced Proposal Category: Ratify Auditors			
5.	To re-appoint PricewaterhouseCoopers LLP, a limited liability partnership organized under the laws of England, as our U.K. statutory auditors, to hold office until the conclusion of the next annual general meeting of shareholders.	Mgmt	For	For
	Enhanced Proposal Category: Ratify Auditors			
6.	To authorize the Audit Committee to determine our U.K. statutory auditors' remuneration for the year ending December 31, 2026.	Mgmt	For	For
	Enhanced Proposal Category: Authorize Board to Fix Remuneration of External Auditor(s)			

Prop. #	Proposal	Proposed by	Proposal Vote	For/Against Management's Recommendation
7.	To receive and adopt our U.K. statutory annual accounts and reports for the year ended December 31, 2025 (the "2025 U.K. Annual Report").	Mgmt	For	For
	Enhanced Proposal Category: Accept Financial Statements and Statutory Reports			
8.	To approve our directors' remuneration report for the year ended December 31, 2025 which is set forth as Annex A to the proxy statement (excluding the directors' remuneration policy set out on pages A-3 to A-22 of the directors' remuneration report and referenced in Proposal 9).	Mgmt	For	For
	Enhanced Proposal Category: Advisory Vote to Ratify Named Executive Officers' Compensation			
9.	To approve the directors' remuneration policy, which is set out on pages A-3 to A-22 of Annex A to the proxy statement.	Mgmt	Against	Against
	Enhanced Proposal Category: Approve Remuneration Policy			

Account Number	Custodian	Ballot Shares	Voted Shares	Shares on Loan	Vote Date
000131268	BNY	15000	15000	0	10-Jun-26

Portland Life Sciences Alternative Fund

CLARITY PHARMACEUTICALS LTD

Security:	Q2517S102	**Agenda Number:**	720515204
Ticker:		**Meeting Type:**	AGM
ISIN:	AU0000165375	**Meeting Date:**	25-Nov-25

Prop. #	Proposal	Proposed by	Proposal Vote	For/Against Management's Recommendation
CMMT	VOTING EXCLUSIONS APPLY TO THIS MEETING FOR PROPOSALS 1,4 TO 7 AND VOTES CAST BY ANY INDIVIDUAL OR RELATED PARTY WHO BENEFIT FROM THE PASSING OF THE PROPOSAL/S WILL BE DISREGARDED BY THE COMPANY. HENCE, IF YOU HAVE OBTAINED BENEFIT OR EXPECT TO OBTAIN FUTURE BENEFIT (AS REFERRED IN THE COMPANY ANNOUNCEMENT) VOTE ABSTAIN ON THE RELEVANT PROPOSAL ITEMS. BY DOING SO, YOU ACKNOWLEDGE THAT YOU HAVE OBTAINED BENEFIT OR EXPECT TO OBTAIN BENEFIT BY THE PASSING OF THE RELEVANT PROPOSAL/S. BY VOTING (FOR OR AGAINST) ON THE ABOVE MENTIONED PROPOSAL/S, YOU ACKNOWLEDGE THAT YOU HAVE NOT OBTAINED BENEFIT NEITHER EXPECT TO OBTAIN BENEFIT BY THE PASSING OF THE RELEVANT PROPOSAL/S AND YOU COMPLY WITH THE VOTING EXCLUSION	Non-Voting		
	Enhanced Proposal Category: No Enhanced Category Available			
1	REMUNERATION REPORT	Mgmt	For	
	Enhanced Proposal Category: Advisory Vote to Ratify Named Executive Officers' Compensation			
2	RE-ELECTION OF DIRECTOR - DR CHRIS ROBERTS AO	Mgmt	For	For
	Enhanced Proposal Category: Elect Director			
3	RE-ELECTION OF DIRECTOR - DR THOMAS RAMDAHL	Mgmt	For	For
	Enhanced Proposal Category: Elect Director			
4	RATIFICATION OF PRIOR PLACEMENT OF SHARES	Mgmt	For	For
	Enhanced Proposal Category: Ratify Past Issuance of Shares			

Investment Company Report

Meeting Date Range: 01-Jul-2025 - 30-Jun-2026 **Report Date:** 27-Aug-2026

Prop. #	Proposal	Proposed by	Proposal Vote	For/Against Management's Recommendation
5	ISSUE OF OPTIONS - DR ALAN TAYLOR (EXECUTIVE CHAIR)	Mgmt	For	For
	Enhanced Proposal Category: Approve Stock Option Plan Grants			
6	ISSUE OF OPTIONS - MICHELLE PARKER (CHIEF EXECUTIVE OFFICER)	Mgmt	For	For
	Enhanced Proposal Category: Approve Stock Option Plan Grants			
7	ISSUE OF OPTIONS - DR COLIN BIGGIN (CHIEF OPERATING OFFICER)	Mgmt	For	For
	Enhanced Proposal Category: Approve Stock Option Plan Grants			

Account Number	Custodian	Ballot Shares	Voted Shares	Shares on Loan	Vote Date
131268	YORK	887235	887235	0	22-Oct-25

Investment Company Report

Portland Life Sciences Alternative Fund

DANAHER CORPORATION

Security:	235851102	**Agenda Number:**	936406950
Ticker:	DHR	**Meeting Type:**	Annual
ISIN:	US2358511028	**Meeting Date:**	05-May-26

Prop. #	Proposal	Proposed by	Proposal Vote	For/Against Management's Recommendation
1a.	To elect the eleven directors named in the attached Proxy Statement to hold office until the 2027 Annual Meeting of Shareholders and until their successors are elected and qualified. Rainer M. Blair Enhanced Proposal Category: Elect Director	Mgmt	For	For
1b.	To elect the eleven directors named in the attached Proxy Statement to hold office until the 2027 Annual Meeting of Shareholders and until their successors are elected and qualified. Feroz Dewan Enhanced Proposal Category: Elect Director	Mgmt	For	For
1c.	To elect the eleven directors named in the attached Proxy Statement to hold office until the 2027 Annual Meeting of Shareholders and until their successors are elected and qualified. Linda Filler Enhanced Proposal Category: Elect Director	Mgmt	For	For
1d.	To elect the eleven directors named in the attached Proxy Statement to hold office until the 2027 Annual Meeting of Shareholders and until their successors are elected and qualified. Charles W. Lamanna Enhanced Proposal Category: Elect Director	Mgmt	For	For
1e.	To elect the eleven directors named in the attached Proxy Statement to hold office until the 2027 Annual Meeting of Shareholders and until their successors are elected and qualified. Teri L. List Enhanced Proposal Category: Elect Director	Mgmt	For	For
1f.	To elect the eleven directors named in the attached Proxy Statement to hold office until the 2027 Annual Meeting of Shareholders and until their successors are elected and qualified. Mitchell P. Rales Enhanced Proposal Category: Elect Director	Mgmt	For	For

Prop. #	Proposal	Proposed by	Proposal Vote	For/Against Management's Recommendation
1g.	To elect the eleven directors named in the attached Proxy Statement to hold office until the 2027 Annual Meeting of Shareholders and until their successors are elected and qualified. Steven M. Rales	Mgmt	For	For
	Enhanced Proposal Category: Elect Director			
1h.	To elect the eleven directors named in the attached Proxy Statement to hold office until the 2027 Annual Meeting of Shareholders and until their successors are elected and qualified. A. Shane Sanders	Mgmt	For	For
	Enhanced Proposal Category: Elect Director			
1i.	To elect the eleven directors named in the attached Proxy Statement to hold office until the 2027 Annual Meeting of Shareholders and until their successors are elected and qualified. Alan G. Spoon	Mgmt	For	For
	Enhanced Proposal Category: Elect Director			
1j.	To elect the eleven directors named in the attached Proxy Statement to hold office until the 2027 Annual Meeting of Shareholders and until their successors are elected and qualified. Raymond C. Stevens, Ph.D	Mgmt	For	For
	Enhanced Proposal Category: Elect Director			
1k.	To elect the eleven directors named in the attached Proxy Statement to hold office until the 2027 Annual Meeting of Shareholders and until their successors are elected and qualified. Elias A. Zerhouni, MD	Mgmt	For	For
	Enhanced Proposal Category: Elect Director			
2.	To ratify the selection of Ernst & Young LLP as Danaher's independent registered public accounting firm for the year ending December 31, 2026.	Mgmt	For	For
	Enhanced Proposal Category: Ratify Auditors			
3.	To approve on an advisory basis the Company's named executive officer compensation.	Mgmt	For	For
	Enhanced Proposal Category: Advisory Vote to Ratify Named Executive Officers' Compensation			
4.	To approve the Company's Amended and Restated Omnibus Incentive Plan.	Mgmt	For	For
	Enhanced Proposal Category: Amend Omnibus Stock Plan			

Investment Company Report

Account Number	Custodian	Ballot Shares	Voted Shares	Shares on Loan	Vote Date
000131268	BNY	1000	1000	0	30-Apr-26
00047580695 ! 5RY0	RBCC	2000	2000	0	30-Apr-26

Portland Life Sciences Alternative Fund

ICON PLC

Security:	G4705A100	**Agenda Number:**	936307657
Ticker:	ICLR	**Meeting Type:**	Annual
ISIN:	IE0005711209	**Meeting Date:**	22-Jul-25

Prop. #	Proposal	Proposed by	Proposal Vote	For/Against Management's Recommendation
1.1	Election of Director: Mr. Ciaran Murray	Mgmt	For	For
	Enhanced Proposal Category: Elect Director			
1.2	Election of Director: Dr. Steve Cutler	Mgmt	For	For
	Enhanced Proposal Category: Elect Director			
1.3	Election of Director: Mr. Rónán Murphy	Mgmt	For	For
	Enhanced Proposal Category: Elect Director			
1.4	Election of Director: Dr. John Climax	Mgmt	For	For
	Enhanced Proposal Category: Elect Director			
1.5	Election of Director: Ms. Julie O'Neill	Mgmt	For	For
	Enhanced Proposal Category: Elect Director			
1.6	Election of Director: Mr. Eugene McCague	Mgmt	For	For
	Enhanced Proposal Category: Elect Director			
1.7	Election of Director: Dr. Linda Grais	Mgmt	For	For
	Enhanced Proposal Category: Elect Director			
1.8	Election of Director: Ms. Anne Whitaker	Mgmt	For	For
	Enhanced Proposal Category: Elect Director			
2.	To review the Company's affairs and consider the Accounts and Reports	Mgmt	For	For
	Enhanced Proposal Category: Accept Financial Statements and Statutory Reports			
3.	To ratify the appointment of EY as the Auditors of the Company and to authorise the Board, acting through its Audit Committee, to fix the Auditors' remuneration	Mgmt	For	For
	Enhanced Proposal Category: Approve Auditors and Authorize Board to Fix Their Remuneration			

Prop. #	Proposal	Proposed by	Proposal Vote	For/Against Management's Recommendation
4.	To authorise the Company to allot shares	Mgmt	For	For
	Enhanced Proposal Category: Approve Issuance of Equity or Equity-Linked Securities with or without Preemptive Rights			
5.	To disapply the statutory pre-emption rights	Mgmt	For	For
	Enhanced Proposal Category: Approve Issuance of Equity or Equity-Linked Securities without Preemptive Rights			
6.	To disapply the statutory pre-emption rights for funding capital investment or acquisitions	Mgmt	For	For
	Enhanced Proposal Category: Approve Issuance of Equity or Equity-Linked Securities without Preemptive Rights			
7.	To authorise the Company and any subsidiary of the Company to make overseas market purchases of shares	Mgmt	For	For
	Enhanced Proposal Category: Authorize Share Repurchase Program			
8.	To authorise the price range at which the Company can reissue shares that it holds as treasury shares	Mgmt	For	For
	Enhanced Proposal Category: Authorize Reissuance of Repurchased Shares			

Account Number	Custodian	Ballot Shares	Voted Shares	Shares on Loan	Vote Date
000131268	BNY	3000	3000	0	26-Jun-25

Portland Life Sciences Alternative Fund

IOVANCE BIOTHERAPEUTICS, INC.

Security: 462260100	**Agenda Number:** 936461641
Ticker: IOVA	**Meeting Type:** Annual
ISIN: US4622601007	**Meeting Date:** 10-Jun-26

Prop. #	Proposal	Proposed by	Proposal Vote	For/Against Management's Recommendation
1.	DIRECTOR			
	Enhanced Proposal Category: Elect Director			
	1 Iain Dukes, D. Phil.	Mgmt	For	For
	2 Athena Countouriotis MD	Mgmt	For	For
	3 Ryan Maynard	Mgmt	For	For
	4 Wayne P. Rothbaum	Mgmt	For	For
	5 F. G. Vogt, Ph.D., J.D.	Mgmt	For	For
	6 Michael Weiser, MD, PhD	Mgmt	For	For
2.	To approve, by non-binding advisory vote, the compensation of our named executive officers;	Mgmt	For	For
	Enhanced Proposal Category: Advisory Vote to Ratify Named Executive Officers' Compensation			
3.	To approve, by non-binding advisory vote, the frequency of our future votes on the compensation of our named executive officers;	Mgmt	1 Year	For
	Enhanced Proposal Category: Advisory Vote on Say on Pay Frequency			
4.	To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2026;	Mgmt	For	For
	Enhanced Proposal Category: Ratify Auditors			

Investment Company Report

Meeting Date Range: 01-Jul-2025 - 30-Jun-2026 **Report Date:** 27-Aug-2026

Prop. #	Proposal	Proposed by	Proposal Vote	For/Against Management's Recommendation
5.	To approve an amendment to our 2020 Employee Stock Purchase Plan to increase the number of shares of the Company's common stock authorized for issuance thereunder by 1,000,000 shares;	Mgmt	For	For
	Enhanced Proposal Category: Amend Qualified Employee Stock Purchase Plan			
6.	To approve an amendment to our Certificate of Incorporation, as amended, to increase the number of authorized shares of the Company's common stock from 500,000,000 shares to 650,000,000 shares; and	Mgmt	For	For
	Enhanced Proposal Category: Increase Authorized Common Stock			
7.	To approve an adjournment of the Annual Meeting, if necessary, to solicit additional proxies if there are not sufficient votes at the time of the Annual Meeting to approve Proposal 6.	Mgmt	For	For
	Enhanced Proposal Category: Adjourn Meeting			

Account Number	Custodian	Ballot Shares	Voted Shares	Shares on Loan	Vote Date
000131268	BNY	130000	130000	0	09-Jun-26

Investment Company Report

Portland Life Sciences Alternative Fund

JANUX THERAPEUTICS, INC.

Security:	47103J105	**Agenda Number:**	936470917
Ticker:	JANX	**Meeting Type:**	Annual
ISIN:	US47103J1051	**Meeting Date:**	11-Jun-26

Prop. #	Proposal	Proposed by	Proposal Vote	For/Against Management's Recommendation
1.1	To elect the two nominees for Class II director named in the accompanying proxy statement to serve for three-year terms until the 2029 Annual Meeting of Stockholders. Natasha Hernday	Mgmt	For	For
	Enhanced Proposal Category: Elect Director			
1.2	To elect the two nominees for Class II director named in the accompanying proxy statement to serve for three-year terms until the 2029 Annual Meeting of Stockholders. Eric Dobmeier	Mgmt	For	For
	Enhanced Proposal Category: Elect Director			
2.	To ratify the selection by the Audit Committee of the Board of Directors of Ernst & Young LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2026.	Mgmt	For	For
	Enhanced Proposal Category: Ratify Auditors			
3.	To approve, on an advisory basis, the compensation of our named executive officers, as disclosed in the proxy statement.	Mgmt	For	For
	Enhanced Proposal Category: Advisory Vote to Ratify Named Executive Officers' Compensation			

Account Number	Custodian	Ballot Shares	Voted Shares	Shares on Loan	Vote Date
000131268	BNY	7000	7000	0	10-Jun-26

Investment Company Report

Portland Life Sciences Alternative Fund

LANTHEUS HOLDINGS, INC.	
Security: 516544103	**Agenda Number:** 936411812
Ticker: LNTH	**Meeting Type:** Annual
ISIN: US5165441032	**Meeting Date:** 30-Apr-26

Prop. #	Proposal	Proposed by	Proposal Vote	For/Against Management's Recommendation
1.1	The election of four Class II directors to our Board of Directors. Ms. Minnie Baylor-Henry	Mgmt	No vote	
	Enhanced Proposal Category: Elect Director			
1.2	The election of four Class II directors to our Board of Directors. Mr. Heinz Mäusli	Mgmt	No vote	
	Enhanced Proposal Category: Elect Director			
1.3	The election of four Class II directors to our Board of Directors. Ms. Julie McHugh	Mgmt	No vote	
	Enhanced Proposal Category: Elect Director			
1.4	The election of four Class II directors to our Board of Directors. Dr. Phuong Khanh (P.K.) Morrow	Mgmt	No vote	
	Enhanced Proposal Category: Elect Director			
2.	The approval, on an advisory basis, of the compensation paid to our named executive officers (commonly referred to as "say on pay").	Mgmt	No vote	
	Enhanced Proposal Category: Advisory Vote to Ratify Named Executive Officers' Compensation			
3.	The approval, on an advisory basis, of the frequency of holding future "say on pay" votes.	Mgmt	No vote	
	Enhanced Proposal Category: Advisory Vote on Say on Pay Frequency			
4.	The approval of an amendment to our Amended and Restated Certificate of Incorporation to declassify our Board of Directors.	Mgmt	No vote	
	Enhanced Proposal Category: Declassify the Board of Directors			
5.	The approval of the Lantheus Holdings, Inc. Amended and Restated 2026 Equity Incentive Plan.	Mgmt	No vote	
	Enhanced Proposal Category: Amend Omnibus Stock Plan			

Investment Company Report

Prop. #	Proposal	Proposed by	Proposal Vote	For/Against Management's Recommendation
6.	The ratification of the appointment of Deloitte & Touche LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2026. Enhanced Proposal Category: Ratify Auditors	Mgmt	No vote	

Account Number	Custodian	Ballot Shares	Voted Shares	Shares on Loan	Vote Date
000131268	BNY	18000	0	0	30-Apr-26

Portland Life Sciences Alternative Fund

NUVALENT, INC.	
Security: 670703107	**Agenda Number:** 936467439
Ticker: NUVL	**Meeting Type:** Annual
ISIN: US6707031075	**Meeting Date:** 16-Jun-26

Prop. #	Proposal	Proposed by	Proposal Vote	For/Against Management's Recommendation
1a.	Election of the following nominees as Class II directors: Michael L. Meyers, M.D., Ph.D.	Mgmt	For	For
	Enhanced Proposal Category: Elect Director			
1b.	Election of the following nominees as Class II directors: Ron Squarer	Mgmt	For	For
	Enhanced Proposal Category: Elect Director			
2.	To approve, on an advisory basis, the compensation paid to our named executive officers.	Mgmt	For	For
	Enhanced Proposal Category: Advisory Vote to Ratify Named Executive Officers' Compensation			
3.	To ratify the appointment of KPMG LLP as Nuvalent, Inc.'s independent registered public accounting firm for the fiscal year ending December 31, 2026.	Mgmt	For	For
	Enhanced Proposal Category: Ratify Auditors			

Account Number	Custodian	Ballot Shares	Voted Shares	Shares on Loan	Vote Date
000131268	BNY	2000	2000	0	15-Jun-26

Portland Life Sciences Alternative Fund

OLEMA PHARMACEUTICALS, INC.

Security:	68062P106	**Agenda Number:**	936479701
Ticker:	OLMA	**Meeting Type:**	Annual
ISIN:	US68062P1066	**Meeting Date:**	17-Jun-26

Prop. #	Proposal	Proposed by	Proposal Vote	For/Against Management's Recommendation
1.	DIRECTOR			
	Enhanced Proposal Category: Elect Director			
	1 Sean Bohen, M.D., Ph.D.	Mgmt	For	For
	2 Scott Garland	Mgmt	For	For
	3 Yi Larson	Mgmt	For	For
	4 Andrew Rappaport	Mgmt	For	For
2.	Approval, on an advisory basis, of the compensation of the Company's named executive officers.	Mgmt	For	For
	Enhanced Proposal Category: Advisory Vote to Ratify Named Executive Officers' Compensation			
3.	Ratification of the selection by the Audit Committee of the Board of Directors of Ernst & Young LLP as the Company's independent registered public accounting firm for the year ending December 31, 2026.	Mgmt	For	For
	Enhanced Proposal Category: Ratify Auditors			

Account Number	Custodian	Ballot Shares	Voted Shares	Shares on Loan	Vote Date
000131268	BNY	50000	50000	0	16-Jun-26

Portland Life Sciences Alternative Fund

PERSPECTIVE THERAPEUTICS, INC.	
Security: 46489V302	**Agenda Number:** 936449847
Ticker: CATX	**Meeting Type:** Annual
ISIN: US46489V3024	**Meeting Date:** 27-May-26

Prop. #	Proposal	Proposed by	Proposal Vote	For/Against Management's Recommendation
1.	DIRECTOR Enhanced Proposal Category: Elect Director			
	1 Lori A. Woods	Mgmt	For	For
	2 Heidi Henson	Mgmt	For	For
	3 R. F. Williamson, III	Mgmt	For	For
	4 Frank Morich, M.D Ph.D	Mgmt	For	For
	5 Johan (Thijs) Spoor	Mgmt	For	For
	6 Maya Martinez-Davis	Mgmt	For	For
2.	To ratify the appointment of WithumSmith+Brown, PC as the independent registered public accounting firm of the Company for the fiscal year ending December 31, 2026. Enhanced Proposal Category: Ratify Auditors	Mgmt	For	For
3.	To approve, on a non-binding advisory basis, the frequency of advisory stockholder votes on the compensation of the Company's named executive officers. Enhanced Proposal Category: Advisory Vote on Say on Pay Frequency	Mgmt	1 Year	For

Account Number	Custodian	Ballot Shares	Voted Shares	Shares on Loan	Vote Date

000131268	BNY	250000	250000	0	21-May-26

Portland Life Sciences Alternative Fund

RADNET, INC.

Security:	750491102	**Agenda Number:**	936450129
Ticker:	RDNT	**Meeting Type:**	Annual
ISIN:	US7504911022	**Meeting Date:**	02-Jun-26

Prop. #	Proposal	Proposed by	Proposal Vote	For/Against Management's Recommendation
1.	DIRECTOR Enhanced Proposal Category: Elect Director			
	1 Howard G. Berger, M.D.	Mgmt	For	For
	2 A. Gregory Sorensen M.D	Mgmt	For	For
	3 Laura P. Jacobs	Mgmt	For	For
	4 Lawrence L. Levitt	Mgmt	For	For
	5 Gregory E. Spurlock	Mgmt	For	For
	6 David L. Swartz	Mgmt	For	For
2.	The ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the year ending December 31, 2026. Enhanced Proposal Category: Ratify Auditors	Mgmt	For	For
3.	An advisory vote to approve the compensation of the Company's Named Executive Officers. Enhanced Proposal Category: Advisory Vote to Ratify Named Executive Officers' Compensation	Mgmt	For	For
4.	The approval of an amendment and restatement to the Company's Equity Incentive Plan. Enhanced Proposal Category: Amend Omnibus Stock Plan	Mgmt	For	For

Account Number	Custodian	Ballot Shares	Voted Shares	Shares on Loan	Vote Date
000131268	BNY	8000	8000	0	02-Jun-26
00047580695 ! 5RY0	RBCC	4000	4000	0	02-Jun-26

Investment Company Report

Meeting Date Range: 01-Jul-2025 - 30-Jun-2026 **Report Date:** 27-Aug-2026

Portland Life Sciences Alternative Fund

RELAY THERAPEUTICS, INC.

Security:	75943R102	**Agenda Number:**	936469293
Ticker:	RLAY	**Meeting Type:**	Annual
ISIN:	US75943R1023	**Meeting Date:**	09-Jun-26

Prop. #	Proposal	Proposed by	Proposal Vote	For/Against Management's Recommendation
1.1	To elect two class III directors to our board of directors, to serve until the 2029 annual meeting of stockholders and until their successor has been duly elected and qualified, or until such director's earlier death, resignation or removal; Douglas S. Ingram Enhanced Proposal Category: Elect Director	Mgmt	For	For
1.2	To elect two class III directors to our board of directors, to serve until the 2029 annual meeting of stockholders and until their successor has been duly elected and qualified, or until such director's earlier death, resignation or removal; Claire Mazumdar, Ph.D. Enhanced Proposal Category: Elect Director	Mgmt	For	For
2.	To consider and act upon an advisory vote on the compensation of our named executive officers; Enhanced Proposal Category: Advisory Vote to Ratify Named Executive Officers' Compensation	Mgmt	For	For
3.	To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2026; Enhanced Proposal Category: Ratify Auditors	Mgmt	For	For
4.	To approve an amendment to our Fourth Amended and Restated Certificate of Incorporation, as amended, to increase the number of authorized shares of our common stock from 300,000,000 to 450,000,000; Enhanced Proposal Category: Increase Authorized Common Stock	Mgmt	For	For

Account Number	Custodian	Ballot Shares	Voted Shares	Shares on Loan	Vote Date
000131268	BNY	10000	10000	0	08-Jun-26

Portland Life Sciences Alternative Fund

SCHRODINGER, INC.

Security:	80810D103	**Agenda Number:**	936474991
Ticker:	SDGR	**Meeting Type:**	Annual
ISIN:	US80810D1037	**Meeting Date:**	22-Jun-26

Prop. #	Proposal	Proposed by	Proposal Vote	For/Against Management's Recommendation
1a.	Election of Class III Directors to serve until the 2029 Annual Meeting of Stockholders. Richard A. Friesner	Mgmt	For	For
	Enhanced Proposal Category: Elect Director			
1b.	Election of Class III Directors to serve until the 2029 Annual Meeting of Stockholders. Rosana Kapeller-Libermann	Mgmt	For	For
	Enhanced Proposal Category: Elect Director			
1c.	Election of Class III Directors to serve until the 2029 Annual Meeting of Stockholders. Gary Sender	Mgmt	For	For
	Enhanced Proposal Category: Elect Director			
2.	Approval of an advisory vote on executive compensation.	Mgmt	For	For
	Enhanced Proposal Category: Advisory Vote to Ratify Named Executive Officers' Compensation			
3.	Approval of an amendment to the Schrödinger, Inc. 2022 Equity Incentive Plan, as amended, to increase the number of shares of common stock available for issuance thereunder by 3,000,000 shares.	Mgmt	For	For
	Enhanced Proposal Category: Amend Omnibus Stock Plan			
4.	Ratification of the appointment of KPMG LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2026.	Mgmt	For	For
	Enhanced Proposal Category: Ratify Auditors			

Account Number	Custodian	Ballot Shares	Voted Shares	Shares on Loan	Vote Date
000131268	BNY	10000	10000	0	18-Jun-26

Investment Company Report

Meeting Date Range: 01-Jul-2025 - 30-Jun-2026 **Report Date:** 27-Aug-2026

Portland Life Sciences Alternative Fund

SIEMENS HEALTHINEERS AG

Security:	D6T479107	**Agenda Number:**	720746049
Ticker:		**Meeting Type:**	AGM
ISIN:	DE000SHL1006	**Meeting Date:**	05-Feb-26

Prop. #	Proposal	Proposed by	Proposal Vote	For/Against Management's Recommendation
CMMT	VOTING MUST BE LODGED WITH SHAREHOLDER DETAILS AS PROVIDED BY YOUR CUSTODIAN. IF NO SHAREHOLDER DETAILS ARE PROVIDED, YOUR INSTRUCTION MAY BE REJECTED.	Non-Voting		
	Enhanced Proposal Category: No Enhanced Category Available			
1	RECEIVE FINANCIAL STATEMENTS AND STATUTORY REPORTS FOR FISCAL YEAR 2025	Non-Voting		
	Enhanced Proposal Category: No Enhanced Category Available			
2	APPROVE ALLOCATION OF INCOME AND DIVIDENDS OF EUR 1.00 PER SHARE	Mgmt	For	For
	Enhanced Proposal Category: Approve Allocation of Income and Dividends			
3.1	APPROVE DISCHARGE OF MANAGEMENT BOARD MEMBER BERNHARD MONTAG FOR FISCAL YEAR 2025	Mgmt	For	For
	Enhanced Proposal Category: Approve Discharge of Management Board Member XXX/Executive Director XXX (INDIVIDUAL RESOLUTION)			
3.2	APPROVE DISCHARGE OF MANAGEMENT BOARD MEMBER JOCHEN SCHMITZ FOR FISCAL YEAR 2025	Mgmt	For	For
	Enhanced Proposal Category: Approve Discharge of Management Board Member XXX/Executive Director XXX (INDIVIDUAL RESOLUTION)			
3.3	APPROVE DISCHARGE OF MANAGEMENT BOARD MEMBER DARLEEN CARON FOR FISCAL YEAR 2025	Mgmt	For	For
	Enhanced Proposal Category: Approve Discharge of Management Board Member XXX/Executive Director XXX (INDIVIDUAL RESOLUTION)			
3.4	APPROVE DISCHARGE OF MANAGEMENT BOARD MEMBER ELISABETH STAUDINGER-LEIBRECHT FOR FISCAL YEAR 2025	Mgmt	For	For
	Enhanced Proposal Category: Approve Discharge of Management Board Member XXX/Executive Director XXX (INDIVIDUAL RESOLUTION)			

Prop. #	Proposal	Proposed by	Proposal Vote	For/Against Management's Recommendation
4.1	APPROVE DISCHARGE OF SUPERVISORY BOARD MEMBER RALF THOMAS FOR FISCAL YEAR 2025	Mgmt	For	For
	Enhanced Proposal Category: Approve Discharge of Supervisory Board Member XXX/Non-Executive Board Member XXX (INDIVIDUAL RESOLUTION)			
4.2	APPROVE DISCHARGE OF SUPERVISORY BOARD MEMBER DOROTHEA SIMON FOR FISCAL YEAR 2025	Mgmt	For	For
	Enhanced Proposal Category: Approve Discharge of Supervisory Board Member XXX/Non-Executive Board Member XXX (INDIVIDUAL RESOLUTION)			
4.3	APPROVE DISCHARGE OF SUPERVISORY BOARD MEMBER KARL-HEINZ STREIBICH FOR FISCAL YEAR 2025	Mgmt	For	For
	Enhanced Proposal Category: Approve Discharge of Supervisory Board Member XXX/Non-Executive Board Member XXX (INDIVIDUAL RESOLUTION)			
4.4	APPROVE DISCHARGE OF SUPERVISORY BOARD MEMBER VANESSA BARTH FOR FISCAL YEAR 2025	Mgmt	For	For
	Enhanced Proposal Category: Approve Discharge of Supervisory Board Member XXX/Non-Executive Board Member XXX (INDIVIDUAL RESOLUTION)			
4.5	APPROVE DISCHARGE OF SUPERVISORY BOARD MEMBER VERONIKA BIENERT FOR FISCAL YEAR 2025	Mgmt	For	For
	Enhanced Proposal Category: Approve Discharge of Supervisory Board Member XXX/Non-Executive Board Member XXX (INDIVIDUAL RESOLUTION)			
4.6	APPROVE DISCHARGE OF SUPERVISORY BOARD MEMBER HARRY BLUNK (UNTIL JUNE 30, 2025) FOR FISCAL YEAR 2025	Mgmt	For	For
	Enhanced Proposal Category: Approve Discharge of Supervisory Board Member XXX/Non-Executive Board Member XXX (INDIVIDUAL RESOLUTION)			
4.7	APPROVE DISCHARGE OF SUPERVISORY BOARD MEMBER ROLAND BUSCH FOR FISCAL YEAR 2025	Mgmt	For	For
	Enhanced Proposal Category: Approve Discharge of Supervisory Board Member XXX/Non-Executive Board Member XXX (INDIVIDUAL RESOLUTION)			
4.8	APPROVE DISCHARGE OF SUPERVISORY BOARD MEMBER STEPHAN BUETTNER FOR FISCAL YEAR 2025	Mgmt	For	For
	Enhanced Proposal Category: Approve Discharge of Supervisory Board Member XXX/Non-Executive Board Member XXX (INDIVIDUAL RESOLUTION)			
4.9	APPROVE DISCHARGE OF SUPERVISORY BOARD MEMBER LARS-CHRISTIAN DINGLINGER FOR FISCAL YEAR 2025	Mgmt	For	For
	Enhanced Proposal Category: Approve Discharge of Supervisory Board Member XXX/Non-Executive Board Member XXX (INDIVIDUAL RESOLUTION)			

Prop. #	Proposal	Proposed by	Proposal Vote	For/Against Management's Recommendation
4.10	APPROVE DISCHARGE OF SUPERVISORY BOARD MEMBER ANDREA FEHRMANN FOR FISCAL YEAR 2025	Mgmt	For	For
	Enhanced Proposal Category: Approve Discharge of Supervisory Board Member XXX/Non-Executive Board Member XXX (INDIVIDUAL RESOLUTION)			
4.11	APPROVE DISCHARGE OF SUPERVISORY BOARD MEMBER NICK HEINDL FOR FISCAL YEAR 2025	Mgmt	For	For
	Enhanced Proposal Category: Approve Discharge of Supervisory Board Member XXX/Non-Executive Board Member XXX (INDIVIDUAL RESOLUTION)			
4.12	APPROVE DISCHARGE OF SUPERVISORY BOARD MEMBER MARION HELMES FOR FISCAL YEAR 2025	Mgmt	For	For
	Enhanced Proposal Category: Approve Discharge of Supervisory Board Member XXX/Non-Executive Board Member XXX (INDIVIDUAL RESOLUTION)			
4.13	APPROVE DISCHARGE OF SUPERVISORY BOARD MEMBER PETER KOERTE FOR FISCAL YEAR 2025	Mgmt	For	For
	Enhanced Proposal Category: Approve Discharge of Supervisory Board Member XXX/Non-Executive Board Member XXX (INDIVIDUAL RESOLUTION)			
4.14	APPROVE DISCHARGE OF SUPERVISORY BOARD MEMBER VOLKER LANG (FROM JULY 1, 2025) FOR FISCAL YEAR 2025	Mgmt	For	For
	Enhanced Proposal Category: Approve Discharge of Supervisory Board Member XXX/Non-Executive Board Member XXX (INDIVIDUAL RESOLUTION)			
4.15	APPROVE DISCHARGE OF SUPERVISORY BOARD MEMBER SARENA LIN FOR FISCAL YEAR 2025	Mgmt	For	For
	Enhanced Proposal Category: Approve Discharge of Supervisory Board Member XXX/Non-Executive Board Member XXX (INDIVIDUAL RESOLUTION)			
4.16	APPROVE DISCHARGE OF SUPERVISORY BOARD MEMBER AXEL PATZE FOR FISCAL YEAR 2025	Mgmt	For	For
	Enhanced Proposal Category: Approve Discharge of Supervisory Board Member XXX/Non-Executive Board Member XXX (INDIVIDUAL RESOLUTION)			
4.17	APPROVE DISCHARGE OF SUPERVISORY BOARD MEMBER ASTRID PLOSS FOR FISCAL YEAR 2025	Mgmt	For	For
	Enhanced Proposal Category: Approve Discharge of Supervisory Board Member XXX/Non-Executive Board Member XXX (INDIVIDUAL RESOLUTION)			
4.18	APPROVE DISCHARGE OF SUPERVISORY BOARD MEMBER PEER SCHATZ FOR FISCAL YEAR 2025	Mgmt	For	For
	Enhanced Proposal Category: Approve Discharge of Supervisory Board Member XXX/Non-Executive Board Member XXX (INDIVIDUAL RESOLUTION)			

Investment Company Report

Meeting Date Range: 01-Jul-2025 - 30-Jun-2026 **Report Date:** 27-Aug-2026

Prop. #	Proposal	Proposed by	Proposal Vote	For/Against Management's Recommendation
4.19	APPROVE DISCHARGE OF SUPERVISORY BOARD MEMBER NATHALIE VON SIEMENS FOR FISCAL YEAR 2025	Mgmt	For	For
	Enhanced Proposal Category: Approve Discharge of Supervisory Board Member XXX/Non-Executive Board Member XXX (INDIVIDUAL RESOLUTION)			
4.20	APPROVE DISCHARGE OF SUPERVISORY BOARD MEMBER HARALD TRETTER FOR FISCAL YEAR 2025	Mgmt	For	For
	Enhanced Proposal Category: Approve Discharge of Supervisory Board Member XXX/Non-Executive Board Member XXX (INDIVIDUAL RESOLUTION)			
4.21	APPROVE DISCHARGE OF SUPERVISORY BOARD MEMBER DOW WILSON FOR FISCAL YEAR 2025	Mgmt	For	For
	Enhanced Proposal Category: Approve Discharge of Supervisory Board Member XXX/Non-Executive Board Member XXX (INDIVIDUAL RESOLUTION)			
5.1	RATIFY PRICEWATERHOUSECOOPERS GMBH AS AUDITORS FOR FISCAL YEAR 2026 AND FOR THE REVIEW OF INTERIM FINANCIAL REPORTS FOR THE FIRST HALF OF FISCAL YEAR 2026	Mgmt	For	For
	Enhanced Proposal Category: Ratify Auditors			
5.2	RATIFY PRICEWATERHOUSECOOPERS GMBH AS AUDITOR FOR SUSTAINABILITY REPORTING FOR FISCAL YEAR 2026	Mgmt	For	For
	Enhanced Proposal Category: Appoint XXX as Auditor for Sustainability Reporting			
6	APPROVE REMUNERATION REPORT	Mgmt	For	For
	Enhanced Proposal Category: Advisory Vote to Ratify Named Executive Officers' Compensation			
7	AMEND ARTICLES RE: SIMPLE MAJORITY FOR ADOPTION OF RESOLUTIONS	Mgmt	For	For
	Enhanced Proposal Category: Amend Articles/Bylaws/Charter -- Non-Routine			
8	APPROVE CREATION OF EUR 338 MILLION POOL OF AUTHORIZED CAPITAL WITH OR WITHOUT EXCLUSION OF PREEMPTIVE RIGHTS	Mgmt	For	For
	Enhanced Proposal Category: Approve Issuance of Equity or Equity-Linked Securities with or without Preemptive Rights			

Investment Company Report

Meeting Date Range: 01-Jul-2025 - 30-Jun-2026 **Report Date:** 27-Aug-2026

Prop. #	Proposal	Proposed by	Proposal Vote	For/Against Management's Recommendation
9	APPROVE ISSUANCE OF WARRANTS/BONDS WITH WARRANTS ATTACHED/CONVERTIBLE BONDS WITHOUT PREEMPTIVE RIGHTS UP TO AGGREGATE NOMINAL AMOUNT OF EUR 6 BILLION; APPROVE CREATION OF EUR 112.8 MILLION POOL OF CAPITAL TO GUARANTEE CONVERSION RIGHTS	Mgmt	For	For
	Enhanced Proposal Category: Authorize Issuance of Warrants/Bonds with Warrants Attached/Convertible Bonds without Preemptive Rights			
10	AUTHORIZE SHARE REPURCHASE PROGRAM AND REISSUANCE OR CANCELLATION OF REPURCHASED SHARES	Mgmt	For	For
	Enhanced Proposal Category: Authorize Share Repurchase Program and Reissuance of Repurchased Shares			
11	AUTHORIZE USE OF FINANCIAL DERIVATIVES WHEN REPURCHASING SHARES	Mgmt	For	For
	Enhanced Proposal Category: Authorize Use of Financial Derivatives			
CMMT	PLEASE NOTE THAT FOLLOWING THE AMENDMENT TO PARAGRAPH 21 OF THE SECURITIES TRADE ACT ON 9TH JULY 2015 AND THE OVER-RULING OF THE DISTRICT COURT IN COLOGNE JUDGMENT FROM 6TH JUNE 2012 THE VOTING PROCESS HAS NOW CHANGED WITH REGARD TO THE GERMAN REGISTERED SHARES. AS A RESULT, IT IS NOW THE RESPONSIBILITY OF THE END-INVESTOR (I.E. FINAL BENEFICIARY) AND NOT THE INTERMEDIARY TO DISCLOSE RESPECTIVE FINAL BENEFICIARY VOTING RIGHTS THEREFORE THE CUSTODIAN BANK / AGENT IN THE MARKET WILL BE SENDING THE VOTING DIRECTLY TO MARKET AND IT IS THE END INVESTORS RESPONSIBILITY TO ENSURE THE REGISTRATION ELEMENT IS COMPLETE WITH THE ISSUER DIRECTLY, SHOULD THEY HOLD MORE THAN 3 % OF THE TOTAL SHARE CAPITAL	Non-Voting		
	Enhanced Proposal Category: No Enhanced Category Available			

Prop. #	Proposal	Proposed by	Proposal Vote	For/Against Management's Recommendation
CMMT	THE VOTE/REGISTRATION DEADLINE AS DISPLAYED ON PROXYEDGE IS SUBJECT TO CHANGE AND WILL BE UPDATED AS SOON AS BROADRIDGE RECEIVES CONFIRMATION FROM THE SUB CUSTODIANS REGARDING THEIR INSTRUCTION DEADLINE. FOR ANY QUERIES PLEASE CONTACT YOUR CLIENT SERVICES REPRESENTATIVE. Enhanced Proposal Category: No Enhanced Category Available	Non-Voting		
CMMT	ACCORDING TO GERMAN LAW, IN CASE OF SPECIFIC CONFLICTS OF INTEREST IN CONNECTION WITH SPECIFIC ITEMS OF THE AGENDA FOR THE GENERAL MEETING YOU ARE NOT ENTITLED TO EXERCISE YOUR VOTING RIGHTS. FURTHER, YOUR VOTING RIGHT MIGHT BE EXCLUDED WHEN YOUR SHARE IN VOTING RIGHTS HAS REACHED CERTAIN THRESHOLDS AND YOU HAVE NOT COMPLIED WITH ANY OF YOUR MANDATORY VOTING RIGHTS NOTIFICATIONS PURSUANT TO THE GERMAN SECURITIES TRADING ACT (WPHG). FOR QUESTIONS IN THIS REGARD PLEASE CONTACT YOUR CLIENT SERVICE REPRESENTATIVE FOR CLARIFICATION. IF YOU DO NOT HAVE ANY INDICATION REGARDING SUCH CONFLICT OF INTEREST, OR ANOTHER EXCLUSION FROM VOTING, PLEASE SUBMIT YOUR VOTE AS USUAL. Enhanced Proposal Category: No Enhanced Category Available	Non-Voting		
CMMT	FURTHER INFORMATION ON COUNTER PROPOSALS CAN BE FOUND DIRECTLY ON THE ISSUER'S WEBSITE (PLEASE REFER TO THE MATERIAL URL SECTION OF THE APPLICATION). IF YOU WISH TO ACT ON THESE ITEMS, YOU WILL NEED TO REQUEST A MEETING ATTEND AND VOTE YOUR SHARES DIRECTLY AT THE COMPANY'S MEETING. COUNTER PROPOSALS CANNOT BE REFLECTED IN THE BALLOT ON PROXYEDGE. Enhanced Proposal Category: No Enhanced Category Available	Non-Voting		

Investment Company Report

Meeting Date Range: 01-Jul-2025 - 30-Jun-2026 **Report Date:** 27-Aug-2026

Prop. #	Proposal	Proposed by	Proposal Vote	For/Against Management's Recommendation
CMMT	FROM 10TH FEBRUARY, BROADRIDGE WILL CODE ALL AGENDAS FOR GERMAN MEETINGS IN ENGLISH ONLY. IF YOU WISH TO SEE THE AGENDA IN GERMAN, THIS WILL BE MADE AVAILABLE AS A LINK UNDER THE 'MATERIAL URL' DROPDOWN AT THE TOP OF THE BALLOT. THE GERMAN AGENDAS FOR ANY EXISTING OR PAST MEETINGS WILL REMAIN IN PLACE. FOR FURTHER INFORMATION, PLEASE CONTACT YOUR CLIENT SERVICE REPRESENTATIVE. Enhanced Proposal Category: No Enhanced Category Available	Non-Voting		
CMMT	INTERMEDIARY CLIENTS ONLY - PLEASE NOTE THAT IF YOU ARE CLASSIFIED AS AN INTERMEDIARY CLIENT UNDER THE SHAREHOLDER RIGHTS DIRECTIVE II, YOU SHOULD BE PROVIDING THE UNDERLYING SHAREHOLDER INFORMATION AT THE VOTE INSTRUCTION LEVEL. IF YOU ARE UNSURE ON HOW TO PROVIDE THIS LEVEL OF DATA TO BROADRIDGE OUTSIDE OF PROXYEDGE, PLEASE SPEAK TO YOUR DEDICATED CLIENT SERVICE REPRESENTATIVE FOR ASSISTANCE Enhanced Proposal Category: No Enhanced Category Available	Non-Voting		
CMMT	19 DEC 2025: PLEASE NOTE THAT IF YOU HOLD CREST DEPOSITORY INTERESTS (CDIS) AND PARTICIPATE AT THIS MEETING, YOU (OR YOUR CREST SPONSORED MEMBER/CUSTODIAN) WILL BE REQUIRED TO INSTRUCT A TRANSFER OF THE RELEVANT CDIS TO THE ESCROW ACCOUNT SPECIFIED IN THE ASSOCIATED CORPORATE EVENT IN THE CREST SYSTEM. THIS TRANSFER WILL NEED TO BE COMPLETED BY THE SPECIFIED CREST SYSTEM DEADLINE. ONCE THIS TRANSFER HAS SETTLED, THE CDIS WILL BE BLOCKED IN THE CREST SYSTEM. THE CDIS WILL TYPICALLY BE RELEASED FROM ESCROW AS SOON AS PRACTICABLE ON RECORD DATE +1 DAY (OR ON MEETING DATE +1 DAY IF NO RECORD DATE APPLIES) UNLESS OTHERWISE SPECIFIED, AND ONLY AFTER THE AGENT HAS CONFIRMED AVAILABILIY OF THE	Non-Voting		

Prop. #	Proposal	Proposed by	Proposal Vote	For/Against Management's Recommendation
	POSITION. IN ORDER FOR A VOTE TO BE ACCEPTED, THE VOTED POSITION MUST BE BLOCKED IN THE REQUIRED ESCROW ACCOUNT IN THE CREST SYSTEM. BY VOTING ON THIS MEETING, YOUR CREST SPONSORED MEMBER/CUSTODIAN MAY USE YOUR VOTE INSTRUCTION AS THE AUTHORIZATION TO TAKE THE NECESSARY ACTION WHICH WILL INCLUDE TRANSFERRING YOUR INSTRUCTED POSITION TO ESCROW. PLEASE CONTACT YOUR CREST SPONSORED MEMBER/CUSTODIAN DIRECTLY FOR FURTHER INFORMATION ON THE CUSTODY PROCESS AND WHETHER OR NOT THEY REQUIRE SEPARATE INSTRUCTIONS FROM YOU Enhanced Proposal Category: No Enhanced Category Available			
CMMT	19 DEC 2025: PLEASE NOTE SHARE BLOCKING WILL APPLY FOR ANY VOTED POSITIONS SETTLING THROUGH EUROCLEAR BANK Enhanced Proposal Category: No Enhanced Category Available	Non-Voting		
CMMT	19 DEC 2025: PLEASE NOTE THAT THIS IS A REVISION DUE TO ADDITION OF COMMENTS. IF YOU HAVE ALREADY SENT IN YOUR VOTES, PLEASE DO NOT VOTE AGAIN UNLESS YOU DECIDE TO AMEND YOUR ORIGINAL INSTRUCTIONS. THANK YOU Enhanced Proposal Category: No Enhanced Category Available	Non-Voting		

Account Number	Custodian	Ballot Shares	Voted Shares	Shares on Loan	Vote Date
131268	YORK	3700	3700	0	08-Jan-26

Investment Company Report

Portland Life Sciences Alternative Fund

TELIX PHARMACEUTICALS LTD	
Security: Q8973A105	**Agenda Number:** 721281020
Ticker:	**Meeting Type:** AGM
ISIN: AU000000TLX2	**Meeting Date:** 21-May-26

Prop. #	Proposal	Proposed by	Proposal Vote	For/Against Management's Recommendation
2	ADOPT THE 2025 REMUNERATION REPORT	Mgmt	For	
	Enhanced Proposal Category: Advisory Vote to Ratify Named Executive Officers' Compensation			
3a	RE-ELECT DR. MARK NELSON AS DIRECTOR	Mgmt	For	For
	Enhanced Proposal Category: Elect Director			
3b	ELECT DAVID GILL AS DIRECTOR	Mgmt	For	For
	Enhanced Proposal Category: Elect Director			
3c	ELECT WILLIAM JELLISON AS DIRECTOR	Mgmt	For	For
	Enhanced Proposal Category: Elect Director			
3d	ELECT DR. MARIA RIVAS AS DIRECTOR	Mgmt	For	For
	Enhanced Proposal Category: Elect Director			
4a	APPROVE THE GRANT OF DEFERRED SHARE RIGHTS TO THE MD AND CEO AS PART OF HIS ANNUAL LONG-TERM VARIABLE REMUNERATION FOR THE FINANCIAL YEAR ENDING 31 DECEMBER 2025	Mgmt	For	For
	Enhanced Proposal Category: Approve Share Plan Grant			
4b	APPROVE THE GRANT OF PERFORMANCE SHARE APPRECIATION RIGHTS TO THE MD AND CEO AS HIS ANNUAL LONG-TERM VARIABLE REMUNERATION FOR THE FINANCIAL YEAR ENDING 31 DECEMBER 2026	Mgmt	For	For
	Enhanced Proposal Category: Approve Stock Option Plan Grants			
5	APPROVE THE EQUITY INCENTIVE PLAN AND THE ISSUE OF EQUITY SECURITIES UNDER THE EQUITY INCENTIVE PLAN	Mgmt	For	
	Enhanced Proposal Category: Approve Omnibus Stock Plan			

Prop. #	Proposal	Proposed by	Proposal Vote	For/Against Management's Recommendation
6	APPROVE POTENTIAL TERMINATION BENEFITS	Mgmt	For	
	Enhanced Proposal Category: Approve or Amend Severance Agreements/Change-in-Control Agreements			
7	APPROVE AN INCREASE TO THE MAXIMUM AGGREGATE REMUNERATION FOR NON-EXECUTIVE DIRECTORS	Mgmt	For	
	Enhanced Proposal Category: Approve Increase in Aggregate Compensation Ceiling for Directors			
8a	APPROVE THE GRANT OF SHARE APPRECIATION RIGHTS TO NON-EXECUTIVE DIRECTOR - MARIE MCDONALD UNDER THE EQUITY INCENTIVE PLAN	Mgmt	For	For
	Enhanced Proposal Category: Approve Stock Option Plan Grants			
8b	APPROVE THE GRANT OF SHARE APPRECIATION RIGHTS TO NON-EXECUTIVE DIRECTOR - DAVID GILL UNDER THE EQUITY INCENTIVE PLAN	Mgmt	For	For
	Enhanced Proposal Category: Approve Stock Option Plan Grants			
8c	APPROVE THE GRANT OF SHARE APPRECIATION RIGHTS TO NON-EXECUTIVE DIRECTOR - WILLIAM JELLISON UNDER THE EQUITY INCENTIVE PLAN	Mgmt	For	For
	Enhanced Proposal Category: Approve Stock Option Plan Grants			
8d	APPROVE THE GRANT OF SHARE APPRECIATION RIGHTS TO NON-EXECUTIVE DIRECTOR - DR. MARIA RIVAS UNDER THE EQUITY INCENTIVE PLAN	Mgmt	For	For
	Enhanced Proposal Category: Approve Stock Option Plan Grants			
9	RATIFY THE PRIOR ISSUE OF CONVERTIBLE BONDS	Mgmt	For	For
	Enhanced Proposal Category: Approve Issuance of Warrants/Convertible Debentures			
CMMT	VOTING EXCLUSIONS APPLY TO THIS MEETING FOR PROPOSALS 2, 4a TO 9 AND VOTES CAST BY ANY INDIVIDUAL OR RELATED PARTY WHO BENEFIT FROM THE PASSING OF THE PROPOSAL/S WILL BE DISREGARDED BY THE COMPANY. HENCE, IF YOU HAVE OBTAINED BENEFIT OR EXPECT TO OBTAIN FUTURE BENEFIT (AS REFERRED IN THE COMPANY ANNOUNCEMENT) VOTE ABSTAIN ON THE RELEVANT PROPOSAL ITEMS. BY DOING SO, YOU ACKNOWLEDGE THAT YOU HAVE	Non-Voting		

Investment Company Report

Meeting Date Range: 01-Jul-2025 - 30-Jun-2026 **Report Date:** 27-Aug-2026

Prop. #	Proposal	Proposed by	Proposal Vote	For/Against Management's Recommendation
	OBTAINED BENEFIT OR EXPECT TO OBTAIN BENEFIT BY THE PASSING OF THE RELEVANT PROPOSAL/S. BY VOTING (FOR OR AGAINST) ON THE ABOVE MENTIONED PROPOSAL/S, YOU ACKNOWLEDGE THAT YOU HAVE NOT OBTAINED BENEFIT NEITHER EXPECT TO OBTAIN BENEFIT BY THE PASSING OF THE RELEVANT PROPOSAL/S AND YOU COMPLY WITH THE VOTING EXCLUSION			

Enhanced Proposal Category: No Enhanced Category Available

Account Number	Custodian	Ballot Shares	Voted Shares	Shares on Loan	Vote Date
131268	YORK	174676	174676	0	30-Apr-26